Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 13:15:e17.
doi: 10.15420/usc.2020.30. eCollection 2021.

Antithrombotics in Complex Percutaneous Coronary Interventions: Type and Duration of Treatment

Despoina-Rafailia Benetou  1 , Charalampos Varlamos  1 , Christos Pappas  1 , Fotios Kolokathis  1 , Dimitrios Alexopoulos  1
Affiliations
Review

Antithrombotics in Complex Percutaneous Coronary Interventions: Type and Duration of Treatment

Despoina-Rafailia Benetou et al. US Cardiol. .

Abstract

Patients undergoing complex percutaneous coronary intervention (PCI) are at an increased risk of atherothrombotic complications. Although dual antiplatelet therapy is the mainstay of treatment for patients undergoing PCI with stent implantation, deciding its type and duration in complex PCI patients has long been considered a challenge for clinicians. This is because the beneficial effects of prolonged treatment and/or more potent antiplatelet agents' use in preventing ischemic events are hindered by a concomitant increase in bleeding complications. The aim of this review is to highlight current evidence regarding the optimal antithrombotic therapy regimens used in complex PCI patients, focusing on the evaluation of both safety and efficacy outcomes as well as addressing future perspectives.

Keywords: P2Y12 inhibitors; Percutaneous coronary intervention; antiplatelet agents; antithrombotics; complex percutaneous coronary intervention; dual antiplatelet therapy; extended dual antiplatelet therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure: DA has received lecturing honoraria/advisory board fees from AstraZeneca, Bayer, Boehringer Ingelheim, Pfizer, Medtronic, Biotronik, and Chiesi Hellas; and is Guest Editor of the antithrombotics in high-risk PCI special collection for US Cardiology Review; this did not influence peer review. All other authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Treatment Options for Extended Antithrombotic Therapy
Figure 2:
Figure 2:. Treatment Algorithm for Patients Undergoing High-risk Percutaneous Coronary Intervention
See this image and copyright information in PMC

References

    1. Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39:213–60. doi: 10.1093/eurheartj/ehx419. - DOI - PubMed
    1. Bortnick AE, Epps KC, Selzer F et al. Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity (from the NHLBI Dynamic Registry). Am J Cardiol. 2014;113:573–9. doi: 10.1016/j.amjcard.2013.10.039. - DOI - PMC - PubMed
    1. Werner N, Nickenig G, Sinning JM. Complex PCI procedures: challenges for the interventional cardiologist. Clin Res Cardiol. 2018;107((Suppl 2)):64–73. doi: 10.1007/s00392-018-1316-1. - DOI - PubMed
    1. Stefanini GG, Serruys PW, Silber S et al. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus eluting stents: a substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol. 2011;57:2221–32. doi: 10.1016/j.jacc.2011.01.036. - DOI - PubMed
    1. Wilensky RL, Selzer F, Johnston J et al. Relation of percutaneous coronary intervention of complex lesions to clinical outcomes (from the NHLBI Dynamic Registry). Am J Cardiol. 2002;90:216–21. doi: 10.1016/S0002-9149(02)02457-8. - DOI - PubMed

LinkOut - more resources